LAL, kinetic chromogenic, recombinant factor C: three ways to the same figure

Bacterial endotoxin is the single most under-discussed contaminant in this market, and the reason is that it does not behave like the contaminants people intuitively worry about. It is not alive. It is a lipopolysaccharide fragment of the outer membrane of Gram-negative bacteria, released in quantity when those bacteria die. It is thermostable enough to survive an autoclave cycle comfortably, small enough to pass a 0.22 micron sterilising filter without hindrance, and pyrogenic in the low nanogram range. A preparation can be perfectly sterile — no viable organism anywhere in the container — and carry an endotoxin burden well above any defensible parenteral limit.

Bioburden, and why the number before the filter matters

A sterilising filter is not an unlimited barrier. Its qualification is expressed as a retention capability under a defined challenge — conventionally a high titre of a small bacterial species per square centimetre of membrane — and its performance in use depends on the load presented to it. A bulk solution carrying a heavy microbial burden presents a filter with a harder problem than one carrying a light burden, and it presents a second problem the filter cannot address at all: the endotoxin released by organisms that die upstream passes through the membrane unimpeded.

Regulated manufacture therefore specifies a pre-filtration bioburden limit, tests against it on every batch, and treats an excursion as an investigation rather than a curiosity. The specification is usually expressed in colony-forming units per hundred millilitres, and a well-controlled process runs far below it.

Of the twenty companies the Journal wrote to, four stated that pre-filtration bioburden is determined on every batch, three stated that it is determined periodically, and the remainder did not answer the question. We regard that distribution as the single most informative result of the correspondence, because bioburden testing is inexpensive, is performed on the bulk rather than the finished container, and is the earliest point at which a problem is cheap to fix.

The compendial sterility test, described plainly

The compendial test proceeds by one of two routes. In membrane filtration, the entire contents of the sampled containers are passed through a retentive membrane which is then divided between two growth media. In direct inoculation, the contents are transferred into the media directly. The media are a fluid thioglycollate medium incubated at thirty to thirty-five degrees for anaerobes and aerobes, and a soybean-casein digest medium incubated at twenty to twenty-five degrees for fungi and aerobes. Incubation runs for fourteen days with periodic examination for visible growth.

The number of containers sampled depends on batch size, and for a parenteral batch above five hundred containers the requirement is twenty. Every one of those twenty is destroyed. Method suitability must be demonstrated separately, because a preserved formulation or an antimicrobial residue can inhibit the very growth the test is looking for, and the bacteriostatic and fungistatic properties of the article have to be neutralised or shown absent before a negative result means anything.¹

A reader who takes nothing else from this section should take the sample size. Twenty containers, fourteen days, destroyed. That is the entire empirical basis of the finished-product sterility claim, and it is why the process argument carries the weight.

What endotoxin is, and why sterility does not address it

Endotoxin is a structural component of the outer membrane of Gram-negative bacteria: a lipopolysaccharide with a lipid A anchor that is the pyrogenic moiety, a core oligosaccharide, and a variable O-antigen chain. It is shed during growth and released in quantity on cell lysis, which means that killing a bacterial population does not remove its endotoxin and may increase the free concentration.

Three physical properties make it a separate discipline. It is thermally robust, surviving autoclave conditions with little loss of pyrogenicity, so terminal sterilisation is not a depyrogenation step. It is small and amphipathic, forming aggregates that pass a 0.22 micron membrane without difficulty, so sterilising filtration is not a depyrogenation step either. And it is active in humans at very low mass — the threshold pyrogenic dose corresponds to something in the region of a nanogram per kilogram of body weight.

The practical consequence is stark. A vial can pass a sterility test, contain no viable organism of any kind, and carry an endotoxin burden many times a defensible parenteral limit, because the organisms responsible died somewhere upstream in a water system, a holding tank or a poorly stored component.²

Three method families, and what each returns

The gel-clot method is the oldest and simplest: lysate is combined with the sample, incubated, and the tube inverted. A firm clot that does not slip is a positive. It is a limit test, and by testing serial dilutions it becomes semi-quantitative. Its virtues are robustness and independence from instrumentation; its limitation is resolution.

Turbidimetric methods read the increasing turbidity produced by clotting protein formation, either as an endpoint at fixed time or kinetically as the time to reach a defined turbidity. Chromogenic methods substitute a synthetic peptide substrate that releases a chromophore when cleaved by the activated enzyme, and read absorbance. The kinetic chromogenic variant — measuring the time to a defined absorbance change against a standard curve — is the method of record for most modern release testing, offering quantitation across several orders of magnitude from a small sample volume.

All three are compendial, all three require a demonstration that the sample matrix neither inhibits nor enhances the reaction, and all three are calibrated against an international reference endotoxin rather than against a mass. A result reported without the method and without the inhibition-enhancement result is, once again, a number without a procedure.³

Recombinant factor C, and the end of an awkward supply chain

The lysate on which conventional endotoxin testing depends is harvested from horseshoe crabs, which are bled and returned to the sea with a mortality that is disputed and not negligible. The assay also inherits the biological variability of a natural product: lysate lots differ, and the cascade includes a branch responsive to beta-glucans, which is a common source of false positives in the presence of cellulose filter residues.

Recombinant factor C reagents replace the harvested cascade with an expressed enzyme, activated by lipopolysaccharide and read chromogenically or fluorimetrically. The response is specific to endotoxin and insensitive to the glucan branch, lot-to-lot consistency is a manufacturing rather than an ecological question, and comparative studies across a wide range of matrices have found agreement with conventional methods well within the variability of the conventional methods themselves.

The reagent has been available for well over a decade and its slow adoption was a regulatory rather than a scientific matter: for years it sat in an alternative-method chapter, obliging users to validate it as a departure. That has now changed, with dedicated chapters in both the United States and European compendia treating recombinant reagents as methods in their own right, and the Journal expects the harvested lysate to become the historical option within this decade.⁴⁵

The endotoxin limit, calculated

The limit is derived, not looked up. For a parenteral product other than an intrathecal one, the threshold pyrogenic dose is taken as five endotoxin units per kilogram of body weight per hour. The endotoxin limit for the product is that figure divided by the maximum dose per kilogram administered within an hour. For an intrathecal route the threshold falls to 0.2 endotoxin units per kilogram, a twenty-five-fold reduction that reflects the absence of the systemic buffering the bloodstream provides.

Work it for a concrete case. A seventy-kilogram subject has an hourly allowance of three hundred and fifty endotoxin units. A vial nominally containing five milligrams of peptide, reconstituted to two millilitres, from which a fifth of a millilitre is drawn, delivers a tenth of the vial contents. If the whole vial carried three hundred and fifty endotoxin units, that draw would deliver thirty-five — a tenth of the allowance. The limit expressed per milligram of peptide is what a certificate should carry, because it is the only form of the number that survives a change in reconstitution volume.

None of the arithmetic is difficult. What is missing from this trade is not the calculation but the measured numerator.⁶

Low endotoxin recovery, and the clean result that is wrong

The most uncomfortable finding in endotoxin testing over the past fifteen years is that certain formulation matrices cause added endotoxin to become undetectable over time. Spike a known quantity of reference endotoxin into a solution containing a non-ionic surfactant and a chelating buffer, hold it, and the recoverable endotoxin declines — sometimes to a small fraction of what was added — while nothing has been removed. The lipopolysaccharide aggregate state has changed, and the assay cannot see what it cannot bind.

The phenomenon is called low endotoxin recovery, and it matters because the combination of polysorbate with citrate or phosphate is extremely common in peptide and protein formulations. A hold-time study — spiking the actual product matrix and measuring recovery across the intended sample storage interval — is the standard mitigation, and it is now expected as part of method suitability for products in that formulation space.

The implication for a reader is narrow but worth stating. A negative endotoxin result on a surfactant-containing formulation, reported without a hold-time recovery study, is weaker evidence than it appears. A negative result on a reconstituted lyophilised peptide in plain water for injection, tested promptly, is considerably stronger.⁷

Depyrogenation, and the step that gets skipped

Because endotoxin survives sterilisation, glass components require a separate treatment. The standard is dry heat: a tunnel or oven cycle at two hundred and fifty degrees or above, validated to achieve at least a three-log reduction in a deliberately applied endotoxin challenge. Vials emerging from a qualified depyrogenation tunnel are both sterile and pyrogen-free, and they remain so only if the subsequent handling maintains it.

Elastomeric closures cannot take that treatment and are instead washed, siliconised and steam-sterilised by a validated cycle, with endotoxin control achieved by the washing step and specified as a limit per stopper. Water for injection is controlled at source, with a compendial endotoxin specification, and a water system is the commonest origin of a pyrogen problem in an otherwise competent facility.

Depyrogenation is also, in the Journal’s experience of asking, the step most frequently absent from descriptions of small fill operations. Autoclaved vials are sterile. Autoclaved vials are not depyrogenated, and an operation that describes its glass preparation solely in terms of autoclaving has told you something specific about what it has not done. We put this point to eleven correspondents; two said their glass is depyrogenated by dry heat with a validated cycle, and one asked us what depyrogenation was, which we took as a straight answer and a useful one.

Container closure integrity, method by method

The compendial guidance divides leak test methods into probabilistic and deterministic families and is explicit about preferring the second. Probabilistic methods — dye ingress under vacuum, microbial immersion challenge, bubble emission — rely on a sequence of stochastic events, and their sensitivity is poor and hard to quantify. A dye ingress test can pass a container with a defect large enough to admit an organism, because the dye happened not to travel.

Deterministic methods measure a physical quantity with a continuous response. Vacuum decay monitors pressure rise in an evacuated test chamber. High-voltage leak detection measures current through the container wall and is well suited to liquid-filled units. Laser-based headspace analysis interrogates the gas inside a sealed container non-destructively, which permits repeated measurement of the same unit across a stability programme. Helium mass spectrometry resolves the smallest defects of any method in routine use.

The threshold that matters is the maximum allowable leakage limit — the defect size below which microbial ingress does not occur under the conditions the product will see. Establishing it for a given package is a piece of work, and once established it converts an argument about seals into a measurement.⁸

What we submitted, and what came back

Between the second and fourth quarters the Journal purchased fourteen vials of lyophilised research peptide from nine suppliers, at catalogue prices, through ordinary channels and without identifying ourselves. Each was photographed sealed, logged, and stored at two to eight degrees on arrival. Twelve were submitted to a contract laboratory accredited to the general competence standard for testing laboratories for bacterial endotoxin determination by kinetic chromogenic assay, with method suitability established for each matrix. Two were submitted for a compendial sterility test by membrane filtration, which destroyed both.

We disclose the following limitations without being asked. Fourteen vials from nine suppliers is not a survey. Single determinations carry the uncertainty of single determinations. A negative sterility result on one vial says nothing about the batch it came from, for exactly the statistical reasons set out above. And a vial that has crossed a border in a padded envelope has a thermal and mechanical history we cannot reconstruct.

What the exercise establishes is narrower than a survey and, we think, worth publishing: that the tests exist, that they are commercially available to a private purchaser at a known price, that the numbers they return are interpretable against a calculable limit, and that nothing prevented any of the nine suppliers from commissioning them first.⁹

A note on method and sourcing

The compendial material in this article is drawn from the current general chapters of the United States Pharmacopeia and the European Pharmacopoeia, read in the original rather than in summary, and from the international standards on aseptic processing and on laboratory competence. Where a chapter has changed status recently — as the recombinant reagent chapters have — we say so, because a reader consulting an older edition will find a different framing.

Where the Journal reports a number it obtained itself, it states the laboratory’s accreditation status, the method family, whether method suitability was established, and the number of determinations. Where we report what a company told us, we distinguish an answer from a refusal and a refusal from a non-response, because those three things are routinely collapsed in coverage of this trade and they are not the same.

Corrections to this department are handled by the standards desk, which reads every letter and records the outcome in the log. Readers who believe a paragraph here overstates its evidence are asked to write to standards@compoundjournal.com; readers with documents to send, including certificates they would like read, should write to letters@compoundjournal.com. We do not publish correspondents’ names without permission and we do not identify the source of a certificate.

We will keep asking the five questions, printing the answers, and recording the refusals as refusals. Two companies changed their certificates after the first round of this correspondence, which is a small result for a year of letters and rather better than none. Documents to letters@compoundjournal.com; disputes about anything above to standards@compoundjournal.com.